60 Participants Needed

MRI Screening for Prostate Cancer

JA
Danny Vesprini, MD profile photo
Overseen ByDanny Vesprini, MD
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Toronto Sunnybrook Regional Cancer Centre
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population.Standard of care screening for men with a BRCA mutation includes PSA testing and digital rectal examination (DRE), the same as with men in the general population.This study is being done to assess whether there is value in using MRI as a screening tool to detect prostate cancer at an earlier stage than may otherwise be detected using standard of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in this specific population at high risk for aggressive disease.

Research Team

DJ

Danny J Vesprini, MD, MSc, FRCPC

Principal Investigator

Sunnybrook Health Sciences Centre

Eligibility Criteria

This trial is for men over 50 who are part of the Male Hereditary Cancer Research Program, have a BRCA1 or BRCA2 mutation, and can undergo an ultrasound biopsy. It's not for those with claustrophobia, MRI contraindications, contrast agent issues, or previous prostate cancer diagnosis.

Inclusion Criteria

I am 50 years old or older.
Enrolled in the Male Hereditary Cancer Research Program at Sunnybrook Health Sciences Center
I am willing and able to have an ultrasound biopsy within 4 weeks after my MRI.
See 1 more

Exclusion Criteria

Claustrophobia
I cannot have MRI contrast due to a medical reason.
I have been diagnosed with prostate cancer before.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

MRI Screening

Participants undergo Multispectral 3T MRI to assess its value as a screening tool for prostate cancer

2 years
Regular MRI visits as per study protocol

Follow-up

Participants are monitored for safety and effectiveness after MRI screening

4 weeks

Treatment Details

Interventions

  • MS3TMRI
  • TRUS Guided Biopsy
Trial Overview The study tests if using MRI as a screening tool helps detect prostate cancer earlier in men at high risk due to BRCA mutations. This is compared to standard PSA testing and digital rectal examination.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: MS3TMRI / TRUS Guided BiopsyExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Toronto Sunnybrook Regional Cancer Centre

Lead Sponsor

Trials
10
Recruited
950+

Women's College Hospital

Collaborator

Trials
108
Recruited
43,700+

Sunnybrook Health Sciences Centre

Collaborator

Trials
693
Recruited
1,569,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security